1. EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY. (12th June 2019) Authors: Gandhi, M.K.; Hoang, T.; Tobin, J.W.; Law, S.C.; Talaulikar, D.; Jain, S.; Vari, F.; Murigneux, V.; Fink, L.; Gunawardana, J.; Gould, C.; Oey, H.; Delecluse, S.; Trappe, R.U.; Merida de Long, L.; Sabdia, M.B.; Bhagat, G.; Hapgood, G.; Blyth, E.; Clancy, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R‐CHOP. (June 2017) Authors: Keane, C.; Gould, C.; Gifford, G.; Stevenson, W.; Birch, S.; Tobin, J.; Talaulikar, D.; Jain, S.; Francis, S.; Matthew, M.; Gabrielli, S.; Abro, E.; Vari, F.; Gandhi, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. (13th November 2015) Authors: Jones, K.; Wockner, L.; Brennan, R. M.; Keane, C.; Chattopadhyay, P. K.; Roederer, M.; Price, D. A.; Cole, D. K.; Hassan, B.; Beck, K.; Gottlieb, D.; Ritchie, D. S.; Seymour, J. F.; Vari, F.; Crooks, P.; Burrows, S. R.; Gandhi, M. K. Journal: Clinical and experimental immunology Issue: Volume 183:Number 2(2016:Feb.) Page Start: 206 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗